<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118560</article-id><article-id pub-id-type="publisher-id">ACM-44912</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_60516535.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  右美托咪定对慢性吸烟患者腹腔镜手术的肺保护作用
  Protective Effect of Dexmedetomidine on Pulmonary Function in Smoking Patients Undergoing Laparoscopic Surgery
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>楠楠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>施</surname><given-names>彩凤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>江</surname><given-names>亚楠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>颖颖</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>荆</surname><given-names>天玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>温</surname><given-names>翠丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院麻醉科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3813</fpage><lpage>3819</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：比较不同剂量右美托咪定对慢性吸烟患者行腹腔镜手术术中、术后呼吸功能的影响。方法：选择普外科择期拟行腹腔镜手术的慢性吸烟患者60例，随机分为3组，0.5 ug∙kg
  <sup>−1</sup>右美托咪定组(D1)和1.0 ug∙kg−1右美托咪定组(D2)在诱导前分别泵注相应剂量的右美托咪定，空白对照组(D0)泵注相同体积生理盐水。麻醉诱导完毕后泵注相应浓度及速度的试验药物，分别于麻醉诱导后(T0)、气腹60 min (T1)、气腹120 min (T2)、气腹结束(T3)、术后6 h (T4)、术后24 h (T5)、术后48 h (T6)抽取桡动脉血2 ml行血气分析，计算氧合指数(OI)、呼吸指数(RI)。计算T0~T3时间点的肺动态顺应性(Cdyn)。记录手术时间、出入量、苏醒时间，随访术后肺部并发症(PPCS)发生情况和住院时间。结果：由于低血压反复使用血管活性药物、及腹腔镜中转为开腹手术，D0及D1组均有一例患者被排除在研究之外。D0组患者在气腹过程中OI逐渐降低、RI逐渐增加(p &lt; 0.05)，D1、D2组患者气腹过程中及术后较术前OI增加、RI降低(p＜0.05)。组间对比，与DO组比较，D1、D2组在气腹过程中及术后氧合指数(OI)增加、呼吸指数(RI)降低(p &lt; 0.05)，与D1组比较，D2组患者术后呼吸指数(RI)降低(p &lt; 0.05)。D1组、D2组术后发生低氧血症患者明显少于D0组(p &lt; 0.05)，D2组苏醒时间显著延长(p &lt; 0.05)。结论：0.5 μg∙kg
  <sup>−1</sup>、1.0 μg∙kg
  <sup>−1</sup>的右美托咪定均能有效改善慢性吸烟患者气腹手术的呼吸水平，进而改善肺功能，而1.0 μg∙kg
  <sup>−1</sup>的右美托咪定会延长患者苏醒时间。
   Objective: To evaluate the effects of different doses of dexmedetomidine on respiration function during and after laparoscopic surgery in chronic smoking patients. Methods: Sixty chronic smokers who were scheduled to undergo laparoscopic surgery in general surgery were randomly divided into 3 groups. 0.5 ug∙kg−1 dexmedetomidine group (D1) and 1.0 ug∙kg
  <sup>−1</sup> dexmedetomidine group (D2) were injected with corresponding doses, Control group (D0) was injected with the same volume of saline to pump the experimental drugs with the corresponding concentration and speed after the induction of anesthesia. 2 ml of radial artery blood was extracted for blood gas analysis, and calculation of oxygenation index (OI), Respiratory index (RI) respectively after induction of anesthesia (T0), 60 minutes of pneumoperitoneum (T1), 120 minutes of pneumoperitoneum (T2), end of pneumoperitoneum (T3), 6 h after operation (T4), 24 h after operation (T5), 48 h after operation (T6). The lung dynamic compliance (Cdyn) at T0~T3 time points is calculated. Operation time, intake and output, recovery time, follow-up postoperative pulmonary complications (PPCS) occurrence and hospital stay are recorded. Results: Due to the repeated use of vasoactive drugs for hypotension and laparoscopic conversion to open surgery, one patient in each of the D0 and D1 groups was excluded from the study. In Group D0, OI gradually decreased and RI gradually increased during the pneumoperitoneum (p &lt; 0.05). During and after the pneumoperitoneum in the D1 and D2 groups, OI increased and RI decreased compared with preoperative (p &lt; 0.05). Compared with the DO group, the oxygenation index (OI) increased during and postoperative pneumoperitoneum, respiratory index (RI) decreased in D1 and D2 groups (p &lt; 0.05). Compared with the D1 group, the postoperative respiratory index (RI) was lower in D2 group (p &lt; 0.05). patients with postoperative hypoxemia in D1 and D2 groups were significantly less than those in D0 group (p &lt; 0.05), and the recovery time in D2 group was significantly prolonged (p &lt; 0.05). 0.5 μg∙kg
  <sup>−1</sup> and 1.0 μg∙kg
  <sup>−1</sup> dexmedetomidine can effectively improve the breathing level of pneumoperitoneum surgery in chronic smoking patients, thereby improving lung function,but 1.0 μg∙kg
  <sup>−1</sup> dexmedetomidine prolongs the patient’s recovery time.
 
</p></abstract><kwd-group><kwd>右美托咪定，吸烟，肺保护，全身麻醉, Dexmedetomidine</kwd><kwd> Smoking</kwd><kwd> Lung Protection</kwd><kwd> Anesthesia</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：比较不同剂量右美托咪定对慢性吸烟患者行腹腔镜手术术中、术后呼吸功能的影响。方法：选择普外科择期拟行腹腔镜手术的慢性吸烟患者60例，随机分为3组，0.5 ug∙kg<sup>−1</sup>右美托咪定组(D1)和1.0 ug∙kg<sup>−1</sup>右美托咪定组(D2)在诱导前分别泵注相应剂量的右美托咪定，空白对照组(D0)泵注相同体积生理盐水。麻醉诱导完毕后泵注相应浓度及速度的试验药物，分别于麻醉诱导后(T0)、气腹60 min (T1)、气腹120 min (T2)、气腹结束(T3)、术后6 h (T4)、术后24 h (T5)、术后48 h (T6)抽取桡动脉血2 ml行血气分析，计算氧合指数(OI)、呼吸指数(RI)。计算T0~T3时间点的肺动态顺应性(Cdyn)。记录手术时间、出入量、苏醒时间，随访术后肺部并发症(PPCS)发生情况和住院时间。结果：由于低血压反复使用血管活性药物、及腹腔镜中转为开腹手术，D0及D1组均有一例患者被排除在研究之外。D0组患者在气腹过程中OI逐渐降低、RI逐渐增加(p &lt; 0.05)，D1、D2组患者气腹过程中及术后较术前OI增加、RI降低(p＜0.05)。组间对比，与DO组比较，D1、D2组在气腹过程中及术后氧合指数(OI)增加、呼吸指数(RI)降低(p &lt; 0.05)，与D1组比较，D2组患者术后呼吸指数(RI)降低(p &lt; 0.05)。D1组、D2组术后发生低氧血症患者明显少于D0组(p &lt; 0.05)，D2组苏醒时间显著延长(p &lt; 0.05)。结论：0.5 μg∙kg<sup>−1</sup>、1.0 μg∙kg<sup>−1</sup>的右美托咪定均能有效改善慢性吸烟患者气腹手术的呼吸水平，进而改善肺功能，而1.0 μg∙kg<sup>−1</sup>的右美托咪定会延长患者苏醒时间。</p></sec><sec id="s2"><title>关键词</title><p>右美托咪定，吸烟，肺保护，全身麻醉</p></sec><sec id="s3"><title>Protective Effect of Dexmedetomidine on Pulmonary Function in Smoking Patients Undergoing Laparoscopic Surgery<sup> </sup></title><p>Nannan Zhang, Caifeng Shi, Yanan Jiang, Yingying Su, Tianyu Jing, Cuili Wen<sup>*</sup></p><p>Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/77-1572526x5_hanspub.png?20210901093818499" /></p><p>Received: Jul. 26<sup>th</sup>, 2021; accepted: Aug. 24<sup>th</sup>, 2021; published: Aug. 31<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/77-1572526x6_hanspub.png?20210901093818499" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the effects of different doses of dexmedetomidine on respiration function during and after laparoscopic surgery in chronic smoking patients. Methods: Sixty chronic smokers who were scheduled to undergo laparoscopic surgery in general surgery were randomly divided into 3 groups. 0.5 ug∙kg<sup>−1</sup> dexmedetomidine group (D1) and 1.0 ug∙kg<sup>−1</sup> dexmedetomidine group (D2) were injected with corresponding doses, Control group (D0) was injected with the same volume of saline to pump the experimental drugs with the corresponding concentration and speed after the induction of anesthesia. 2 ml of radial artery blood was extracted for blood gas analysis, and calculation of oxygenation index (OI), Respiratory index (RI) respectively after induction of anesthesia (T0), 60 minutes of pneumoperitoneum (T1), 120 minutes of pneumoperitoneum (T2), end of pneumoperitoneum (T3), 6 h after operation (T4), 24 h after operation (T5), 48 h after operation (T6). The lung dynamic compliance (Cdyn) at T0~T3 time points is calculated. Operation time, intake and output, recovery time, follow-up postoperative pulmonary complications (PPCS) occurrence and hospital stay are recorded. Results: Due to the repeated use of vasoactive drugs for hypotension and laparoscopic conversion to open surgery, one patient in each of the D0 and D1 groups was excluded from the study. In Group D0, OI gradually decreased and RI gradually increased during the pneumoperitoneum (p &lt; 0.05). During and after the pneumoperitoneum in the D1 and D2 groups, OI increased and RI decreased compared with preoperative (p &lt; 0.05). Compared with the DO group, the oxygenation index (OI) increased during and postoperative pneumoperitoneum, respiratory index (RI) decreased in D1 and D2 groups (p &lt; 0.05). Compared with the D1 group, the postoperative respiratory index (RI) was lower in D2 group (p &lt; 0.05). patients with postoperative hypoxemia in D1 and D2 groups were significantly less than those in D0 group (p &lt; 0.05), and the recovery time in D2 group was significantly prolonged (p &lt; 0.05). 0.5 μg∙kg<sup>−1</sup> and 1.0 μg∙kg<sup>−1</sup> dexmedetomidine can effectively improve the breathing level of pneumoperitoneum surgery in chronic smoking patients, thereby improving lung function,but 1.0 μg∙kg<sup>−1</sup> dexmedetomidine prolongs the patient’s recovery time.</p><p>Keywords:Dexmedetomidine, Smoking, Lung Protection, Anesthesia</p><disp-formula id="hanspub.44912-formula47"><graphic xlink:href="//html.hanspub.org/file/77-1572526x7_hanspub.png?20210901093818499"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/77-1572526x8_hanspub.png?20210901093818499" /> <img src="//html.hanspub.org/file/77-1572526x9_hanspub.png?20210901093818499" /></p></sec><sec id="s5"><title>1. 引言</title><p>吸烟是慢性阻塞性肺疾病发生及发展最大的危险因素之一，香烟烟雾中的尼古丁、焦油和一氧化碳等大量颗粒物和有害气体会导致并加剧肺部的氧化应激、炎症反应和肺血管重构 [<xref ref-type="bibr" rid="hanspub.44912-ref1">1</xref>]。这些炎性介质可破坏肺和气道的弹性纤维，导致其顺应性下降、气道分泌增加和呼吸道不可逆性受限 [<xref ref-type="bibr" rid="hanspub.44912-ref2">2</xref>]。腹腔镜手术以其创口小、术后恢复快等优势更易被病人接受，然而气腹后腹内压升高、膈肌上抬，再加之头高脚低位的影响，均会对患者的呼吸功能产生影响 [<xref ref-type="bibr" rid="hanspub.44912-ref3">3</xref>]。先前的研究已证实右美托咪定可通过调节炎症反应、抑制氧化应激、缓解缺血再灌注等多种途径产生肺保护作用 [<xref ref-type="bibr" rid="hanspub.44912-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.44912-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44912-ref6">6</xref>]，而能否缓解香烟烟雾引起的肺损伤则少见报道。因此，本研究探讨右美托咪定对慢性吸烟患者行腹腔镜手术的肺保护作用。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选择青岛大学附属医院2020年10月至2021年5月普外科择期拟行腹腔镜手术的慢性吸烟患者60例，采用随机数字表法分为3组，空白对照组(D0)、0.5 ug∙kg<sup>−</sup><sup>1</sup>右美托咪定组(D1)和1.0 ug∙kg<sup>−</sup><sup>1</sup>右美托咪定组(D2)各20例。本研究经青岛大学附属医院医学伦理委员会审核同意，患者及其家属签署知情同意书。入选标准：①慢性吸烟患者(烟龄 ≥ 5年，吸烟量 ≥ 10支/天)；②术前肺功能检查一秒用力呼气容积(FEV1)/预计值百分比 ≥ 80%，FEV1/FVC &gt; 70%，每分钟最大通气量(MVV) &gt; 80 L/min；③ASA分级I~II级；④BMI &lt; 28 kg/m<sup>−</sup><sup>2</sup>；⑤年龄25~65岁；⑥均由同一医生团队进行手术。排除标准：①术前2周内急性上呼吸道感；②既往哮喘、肺间质纤维化等肺部疾病史；③长期应用镇静催眠类药物；④严重精神或神经疾病病史。剔除标准：①术中SpO2 &lt; 95%；②术中低血压需反复应用血管活性药物；③由腹腔镜中转为开腹手术。</p></sec><sec id="s6_2"><title>2.2. 麻醉方法</title><p>所有患者术前常规戒烟3天。患者均无术前用药，常规禁饮食8 h。入室后开放上肢静脉通路，输注乳酸钠林格液6 ml∙kg<sup>−</sup><sup>1</sup>。局麻下行左桡动脉穿刺置管，连接IntelliVue MP 80多功能监测系统(Philips公司，荷兰)，及该系统配备的脑电双频谱指数M1034A模块和ASPECT标准四电极传感器(Aspect公司，美国)常规监测心电图(ECG)、心率(HR)、平均动脉压(MAP)、脉搏血氧饱和度(SpO2)及脑电双频指数(BIS)。由非参与试验观察的麻醉科护士查看随机数字表，按照分组配置药物。D1、D2组分别将右美托咪定(商品名佑必妥，江苏恒瑞医药公司，规格为2 mL：200 μg，批号：21011531) 0.5 μg∙kg<sup>−</sup><sup>1</sup>、1.0 μg∙kg<sup>−</sup><sup>1</sup>用氯化钠注射液稀释成20 mL泵注，D0组泵注同等容量生理盐水，三组均使用Graseby3100微量泵(Graseby公司，英国)以120 mL∙h<sup>−</sup><sup>1</sup>的泵速静脉泵注10 min。随后三组均以20 mL∙h<sup>−</sup><sup>1</sup>泵注至腹腔冲洗。麻醉诱导：依次缓慢静脉注射利多卡因1.5 mg/kg、依托咪酯0.2 mg/kg、丙泊酚1.0 mg/kg、枸橼酸舒芬太尼0.3 μg/kg、维库溴铵0.12 mg/kg。托下颌扣紧面罩纯氧加压通气，待BIS &lt; 50时行气管插管。确认导管位置无误后连接麻醉呼吸机，吸入氧流量1.5 L/min，潮气量8 ml/kg、调整通气频率维持呼气末CO<sub>2</sub>为35~45 mmHg。术中使用Diprifusor靶控输注系统(Graseby 3500注射泵和TCI软件，Graseby公司，英国)输注1%丙泊酚(商品名：得普利麻，规格为50 mL：500 mg，意大利AstraZeneca公司，批号：RL584)维持麻醉，根据患者BIS值调整靶控浓度，根据手术需要追加舒芬太尼和维库溴铵。术中出现心动过缓(HR &lt; 50次/min)，静注阿托品0.2 mg；出现低血压(MAP下降幅度超过基础值的30%)时，给予麻黄碱6 mg；出现高血压(MAP升高幅度超过基础值的30%)时，单次静注硝酸异山梨酯注射液(商品名：爱倍) 1 mg。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>分别于麻醉诱导后(T0)、气腹60 min (T1)、气腹120 min (T2)、气腹结束(T3)、术后6 h (T4)、术后24 h (T5)、术后48 h (T6)抽取桡动脉血2 ml行血气分析，计算氧合指数(OI)、呼吸指数(RI)。计算T0~T3时间点的肺动态顺应性(Cdyn)。记录术中资料，包括手术时间(开始切皮至缝皮结束时间)、出入量、苏醒时间(缝皮结束至患者呼之能应的时间)。术后对患者进行随访记录术后肺部并发症(PPCS)发生情况和住院时间。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS 26.0统计软件处理数据。计量资料以 X &#175; &#177; s 描述，组间比较采用单因素方差分析，组内比较采用重复测量方差分析，两两比较采用LSD检验；计数资料比较采用c2检验。以p &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>试验共入选了58例普外科择期行腹腔镜手术的患者。D0组一例患者由于低血压反复使用血管活性药物、D1组一例患者由腹腔镜中转为开腹手术被排除在研究之外。</p><sec id="s7_1"><title>3.1. 一般情况和术中情况的比较</title><p>3组患者年龄、体重指数、手术时间、出入量、每日吸烟量、烟龄等方面差异无统计学意义(p &gt; 0.05)，苏醒时间D2组明显长于D0与D1组(p &lt; 0.05)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of 3 groups who in general condition and intraoperative conditio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >D0组(n = 19)</th><th align="center" valign="middle" >D1组(n = 19)</th><th align="center" valign="middle" >D2组(n = 20)</th></tr></thead><tr><td align="center" valign="middle" >年龄/岁</td><td align="center" valign="middle" >55.7 &#177; 7.2</td><td align="center" valign="middle" >55.9 &#177; 10.0</td><td align="center" valign="middle" >56.1 &#177; 9.4</td></tr><tr><td align="center" valign="middle" >体重指数/kg∙m<sup>−</sup><sup>2</sup></td><td align="center" valign="middle" >23.6 &#177; 4.0</td><td align="center" valign="middle" >22.7 &#177; 3.6</td><td align="center" valign="middle" >22.3 &#177; 4.1</td></tr><tr><td align="center" valign="middle" >手术时间/min</td><td align="center" valign="middle" >179.8 &#177; 15.1</td><td align="center" valign="middle" >173.2 &#177; 16.8</td><td align="center" valign="middle" >180.0 &#177; 20.5</td></tr><tr><td align="center" valign="middle" >入量/ml</td><td align="center" valign="middle" >1884.6 &#177; 206.4</td><td align="center" valign="middle" >1934.2 &#177; 196.7</td><td align="center" valign="middle" >1927.0 &#177; 146.9</td></tr><tr><td align="center" valign="middle" >出量/ml</td><td align="center" valign="middle" >887.3 &#177; 230.1</td><td align="center" valign="middle" >914.3 &#177; 250.0</td><td align="center" valign="middle" >906.3 &#177; 194.2</td></tr><tr><td align="center" valign="middle" >每日吸烟/支</td><td align="center" valign="middle" >25.7 &#177; 7.2</td><td align="center" valign="middle" >24.0 &#177; 5.5</td><td align="center" valign="middle" >24.5 &#177; 6.3</td></tr><tr><td align="center" valign="middle" >烟龄/年</td><td align="center" valign="middle" >28.2 &#177; 4.5</td><td align="center" valign="middle" >27.6 &#177; 8.0</td><td align="center" valign="middle" >27.2 &#177; 6.5</td></tr><tr><td align="center" valign="middle" >苏醒时间/min</td><td align="center" valign="middle" >15.8 &#177; 7.1</td><td align="center" valign="middle" >16.8 &#177; 6.9</td><td align="center" valign="middle" >23.8 &#177; 4.3<sup>ab</sup></td></tr></tbody></table></table-wrap><p>表1. 3组患者一般情况和术中情况的比较 x &#175; &#177; S</p><p>D0：生理盐水组；D1：0.5 μg∙kg<sup>−</sup><sup>1</sup>右美托咪定组；D2：1.0 μg∙kg<sup>−</sup><sup>1</sup>右美托咪定组，经单因素方差分析，两两比较，与D0组比较，ap &lt; 0.05；与D1组比较bp &lt; 0.05。</p></sec><sec id="s7_2"><title>3.2. 呼吸指标的比较</title><p>三组患者诱导后OI、RI无显著差异(p &gt; 0.05)。与诱导后基础值相比，在气腹120 min (T2)、气腹结束(T3)时D0组患者氧合指数(OI)降低、呼吸指数(RI)增高(p &lt; 0.05)。与诱导后基础值相比，在气腹120 min (T2)、气腹结束(T3)、术后24 h (T5)、术后48 h时(T6) D1、D2组患者氧合指数(OI)增加，呼吸指数(RI)降低(p &lt; 0.05)。组间对比，与DO组比较，D1、D2组在气腹过程中及术后氧合指数(OI)增加，呼吸指数(RI)降低(p &lt; 0.05)。与D1组比较，D2组患者术后呼吸指数(RI)降低(p &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of the respiratory indexes of the 3 groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >氧合指数(OI)</th><th align="center" valign="middle" >呼吸指数(RI)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="7"  >D0组(n = 19)</td><td align="center" valign="middle" >T0</td><td align="center" valign="middle" >367.16 &#177; 56.84</td><td align="center" valign="middle" >0.75 &#177; 0.13</td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >380.82 &#177; 76.86</td><td align="center" valign="middle" >0.69 &#177; 0.17</td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >310.74 &#177; 46.48<sup>a</sup></td><td align="center" valign="middle" >1.26 &#177; 0.13<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >304.48 &#177; 59.83<sup>a</sup></td><td align="center" valign="middle" >1.28 &#177; 0.15<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T4</td><td align="center" valign="middle" >319.49 &#177; 82.25<sup>a</sup></td><td align="center" valign="middle" >0.88 &#177; 0.17<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T5</td><td align="center" valign="middle" >392.21 &#177; 76.34</td><td align="center" valign="middle" >0.89 &#177; 0.25<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T6</td><td align="center" valign="middle" >379.32 &#177; 95.44</td><td align="center" valign="middle" >0.80 &#177; 0.29</td></tr><tr><td align="center" valign="middle"  rowspan="7"  >D1组(n = 19)</td><td align="center" valign="middle" >T0</td><td align="center" valign="middle" >359.02 &#177; 63.64</td><td align="center" valign="middle" >0.71 &#177; 0.15</td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >389.74 &#177; 43.02</td><td align="center" valign="middle" >0.72 &#177; 0.20</td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >458.37 &#177; 74.35<sup>ab</sup></td><td align="center" valign="middle" >0.82 &#177; 0.24<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >401.26 &#177; 46.76<sup>ab</sup></td><td align="center" valign="middle" >0.88 &#177; 0.16<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T4</td><td align="center" valign="middle" >474.81 &#177; 37.87<sup>ab</sup></td><td align="center" valign="middle" >0.79 &#177; 0.19</td></tr><tr><td align="center" valign="middle" >T5</td><td align="center" valign="middle" >470.19 &#177; 73.24<sup>ab</sup></td><td align="center" valign="middle" >0.77 &#177; 0.20<sup>b</sup></td></tr><tr><td align="center" valign="middle" >T6</td><td align="center" valign="middle" >412.63 &#177; 92.43<sup>a</sup></td><td align="center" valign="middle" >0.60 &#177; 0.21<sup>ab</sup></td></tr><tr><td align="center" valign="middle"  rowspan="7"  >D2组(n = 20)</td><td align="center" valign="middle" >T0</td><td align="center" valign="middle" >362.36 &#177; 62.23</td><td align="center" valign="middle" >0.69 &#177; 0.11</td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >389.48 &#177; 93.86</td><td align="center" valign="middle" >0.72 &#177; 0.15</td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >489.54 &#177; 85.92<sup>ab</sup></td><td align="center" valign="middle" >0.74 &#177; 0.27<sup>b</sup></td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >450.87 &#177; 62.04<sup>ab</sup></td><td align="center" valign="middle" >0.84 &#177; 0.13<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T4</td><td align="center" valign="middle" >480.59 &#177; 82.42<sup>ab</sup></td><td align="center" valign="middle" >0.75 &#177; 0.14<sup>b</sup></td></tr><tr><td align="center" valign="middle" >T5</td><td align="center" valign="middle" >449.25 &#177; 73.49<sup>ab</sup></td><td align="center" valign="middle" >0.66 &#177; 0.20<sup>bc</sup></td></tr><tr><td align="center" valign="middle" >T6</td><td align="center" valign="middle" >437.77 &#177; 60.37<sup>ab</sup></td><td align="center" valign="middle" >0.47 &#177; 0.18<sup>abc</sup></td></tr></tbody></table></table-wrap><p>表2. 3组患者呼吸指标的比较 X &#175; &#177; S</p><p>D0：生理盐水组；D1：0.5 μg∙kg<sup>−</sup><sup>1</sup>右美托咪定组；D2：1.0 μg∙kg<sup>−</sup><sup>1</sup>右美托咪定组，T0麻醉诱导后、T1：气腹60 min、T2：气腹120 min、T3：气腹结束、T4：术后6 h、T5：术后24 h、T6：术后48 h。经重复测量的方差分析，与T0比较，ap &lt; 0.05；经单因素方差分析，与D0组比较，bp &lt; 0.05，与D1组比cp &lt; 0.05。</p></sec><sec id="s7_3"><title>3.3. 术后肺部并发症及住院时间比较</title><p>三组患者住院时间及肺部感染比例无显著差异(p &gt; 0.05)。D1 组、D2组术后发生低氧血症患者明显少于D0组(p &lt; 0.05)，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of the postoperative conditions of the 3 groups of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >肺部感染[例(%)]</th><th align="center" valign="middle" >低氧血症[例(%)]</th><th align="center" valign="middle" >住院时间(d, x &#177; s)</th></tr></thead><tr><td align="center" valign="middle" >D0组(n = 19)</td><td align="center" valign="middle" >1 (5.3%)</td><td align="center" valign="middle" >6 (31.6%)</td><td align="center" valign="middle" >7.2 &#177; 2.6</td></tr><tr><td align="center" valign="middle" >D1组(n = 19)</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" >1 (5.3%)<sup>a</sup></td><td align="center" valign="middle" >6.5 &#177; 2.3</td></tr><tr><td align="center" valign="middle" >D2组(n = 20)</td><td align="center" valign="middle" >1 (5.0%)</td><td align="center" valign="middle" >1 (5.3%)<sup>a</sup></td><td align="center" valign="middle" >6.7 &#177; 3.1</td></tr></tbody></table></table-wrap><p>表3. 3组患者术后情况比较</p><p>D0：生理盐水组；D1：0.5 μg∙kg<sup>−</sup><sup>1</sup>右美托咪定组；D2：1.0 μg∙kg<sup>−</sup><sup>1</sup>右美托咪定组，经χ2检验，与D0组比较，ap &lt; 0.05，与D1组比较，bp &lt; 0.05。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>右美托咪定作为高选择性α2肾上腺素能受体激动剂具有镇静、镇痛、抗交感和维持血流动力学稳定等多种作用，已经被广泛应用于术中及ICU的患者。越来越多的研究表明，右美托咪定可以通过抑制炎症反应 [<xref ref-type="bibr" rid="hanspub.44912-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44912-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.44912-ref9">9</xref>]、氧化应激 [<xref ref-type="bibr" rid="hanspub.44912-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44912-ref11">11</xref>] 和细胞凋亡 [<xref ref-type="bibr" rid="hanspub.44912-ref12">12</xref>] 产生器官保护作用。动物实验研究表明，强效的α2肾上腺素能受体激动剂右美托咪定可以抑制香烟烟雾引起的肺泡和支气管上皮细胞损伤 [<xref ref-type="bibr" rid="hanspub.44912-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.44912-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.44912-ref15">15</xref>]，而临床研究鲜有发表。</p><p>右美托咪定对慢性吸烟患者产生肺保护的可能机制如下：①可提高肺泡和支气管上皮细胞活力；②不仅抑制了香烟烟雾引起的NF-κB和COX2的活化，还可以逆转包括TNF-α、IL-1β和IL-6在内的促炎因子的产生；③阻止了氧化应激的发；④降低了凋亡细胞的比例，并恢复了抗凋亡蛋白和促凋亡蛋白(包括Bcl-2，Bax和caspase-3)之间的平衡。Hong等人 [<xref ref-type="bibr" rid="hanspub.44912-ref16">16</xref>] 用香烟烟雾提取物(CSE)处理支气管和肺泡上皮细胞24小时，以模拟香烟烟雾引起的肺损伤。结果表明，CSE诱导的炎症因子TNF-α、IL-1β和IL-6活性的增加以及细胞凋亡蛋白失衡被Dex部分减弱，除此之外Dex还可以通过恢复NF-κB、COX2、mnSOD、过氧化氢酶和ROS的水平减轻肺损伤。</p><p>本研究通过应用不同剂量的右美托咪定及空白对照组对比了慢性吸烟患者腹腔镜手术术中、术后呼吸相关的指标。氧合指数(OI)通常是用于评价肺换气和氧合的指标，可以反应机体吸氧情况下缺氧的情况，该数值与肺内分流密切相关，被用作肺损伤严重程度的指标 [<xref ref-type="bibr" rid="hanspub.44912-ref17">17</xref>]。其正常值为400~500 mmHg，当OI &lt; 300 mmHg时，提示呼吸功能障碍。呼吸指数(RI)是反映肺部氧气交换难易程度的指标，正常值 &lt; 1，当&gt;1时，说明氧合功能降低。未使用右美托咪定的患者在气腹过程中氧合指数逐渐降低、呼吸指数逐渐增加，随着手术结束后患者持续吸氧及CO<sub>2</sub>吸收、排出，逐渐恢复到术前水平。持续应用右美托咪定的两组气腹过程中及术后较术前氧合指数增加、呼吸指数降低，除此之外，应用右美托咪定的患者术后肺部感染的几率大大下降，这可能与右美托咪定作用于第四脑室旁的蓝斑核产生有效镇静、协助镇痛作用相关，患者术后因疼痛限制有效咳嗽、排痰的可能下降，使得肺部感染发生率降低。1.0 μg∙kg<sup>−</sup><sup>1</sup>右美托咪定组在术后24、48 h呼吸指数比0.5 μg∙kg<sup>−</sup><sup>1</sup>右美托咪定组及生理盐水组降低，提示大剂量右美托咪定可能有长期预后的受益，但该组患者苏醒时间显著延长。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，0.5 μg∙kg<sup>−</sup><sup>1</sup>、1.0 μg∙kg<sup>−</sup><sup>1</sup>的右美托咪定均能有效改善慢性吸烟患者气腹手术的呼吸水平，进而改善肺功能。笔者认为，若患者术后48 h以上的呼吸指数、氧和指数能持续改善，则苏醒时间延长并不成为此药物的弊端。本研究样本量偏小，下一步研究除扩大样本量外，还需进一步随访观察1.0 μg∙kg<sup>−</sup><sup>1</sup>的右美托咪定是否能改善患者的长期预后。</p></sec><sec id="s10"><title>文章引用</title><p>张楠楠,施彩凤,江亚楠,苏颖颖,荆天玉,温翠丽. 右美托咪定对慢性吸烟患者腹腔镜手术的肺保护作用Protective Effect of Dexmedetomidine on Pulmonary Function in Smoking Patients Undergoing Laparoscopic Surgery[J]. 临床医学进展, 2021, 11(08): 3813-3819. https://doi.org/10.12677/ACM.2021.118560</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44912-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ballweg, K., Mutze, K., Königshoff, M., Eickelberg, O. and Meiners, S. (2014) Cigarette Smoke Extract Affects Mitochondrial Function in Alveolar Epithelial Cells. American Journal of Physiology-Lung Cellular and Molecular Physiology, 307, L895-L907. &lt;br&gt;https://doi.org/10.1152/ajplung.00180.2014</mixed-citation></ref><ref id="hanspub.44912-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Chu, S., Zhong, X., Lao, Q., He, Z. and Liang, Y. (2013) Increased Expression of CD4+IL-17+ Cells in the Lung Tissue of Patients with Stable Chronic Obstructive Pulmonary Disease (COPD) and Smokers. International Immunopharmacology, 15, 58-66. &lt;br&gt;https://doi.org/10.1016/j.intimp.2012.10.018</mixed-citation></ref><ref id="hanspub.44912-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Baki, E.D., Kokulu, S., Bal, A., Ela, Y., Sivaci, R.G., Yoldas, M., Çelik, F. and Ozturk, N.K. (2014) Evaluation of Low Tidal Volume with Positive End-Expiratory Pressure Application Effects on Arterial Blood Gases during Laparoscopic Surgery. Journal of the Chinese Medical Association, 77, 374-378. &lt;br&gt;https://doi.org/10.1016/j.jcma.2014.04.007</mixed-citation></ref><ref id="hanspub.44912-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Jia, S., Gao, T., Zhang, R., Liu, Z. and Wang, Y. (2018) Dexmedetomidine Mitigate Acute Lung Injury by Inhibiting IL-17-Induced Inflammatory Reaction. Immunobiology, 23, 32-37.  
&lt;br&gt;https://doi.org/10.1016/j.imbio.2017.10.017</mixed-citation></ref><ref id="hanspub.44912-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">刘贵春, 孙凯, 付红光, 董铁立, 袁峰. 右美托咪啶对老年肺癌患者单肺通气时肺损伤及CHOP蛋白表达的影响[J]. 中华医学杂志, 2020, 100(1): 37-41.</mixed-citation></ref><ref id="hanspub.44912-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Li, P., Han, J., Zhang, D., Cao, S. and Su, C. (2020) Effects of Dexmedetomidine on Oxidative Stress and Inflammatory Response in Lungs during Mechanical Ventilation in COPD Rats. Experimental and Therapeutic Medicine, 19, 1219-1224. &lt;br&gt;https://doi.org/10.3892/etm.2019.8341</mixed-citation></ref><ref id="hanspub.44912-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Xiang, H., Hu, B., Li, Z. and Li, J. (2014) Dexmedetomidine Controls Systemic Cytokine Levels through the Cholinergic Anti-Inflammatory Pathway. Inflammation, 37, 1763-1770. &lt;br&gt;https://doi.org/10.1007/s10753-014-9906-1</mixed-citation></ref><ref id="hanspub.44912-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Liang, H., Liu, H.Z., Wang, H.B., Zhong, J.Y., Yang, C.X. and Zhang, B. (2017) Dexmedetomidine Protects against Cisplatin-Induced Acute Kidney Injury in Mice through Regulating Apoptosis and Inflammation. Inflammation Research, 66, 399-411. &lt;br&gt;https://doi.org/10.1007/s00011-017-1023-9</mixed-citation></ref><ref id="hanspub.44912-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Yamakita, S., Matsuda, M., Yamaguchi, Y., Sawa, T. and Amaya, F. (2017) Dexmedetomidine Prolongs Levobupivacaine Analgesia via Inhibition of Inflammation and p38 MAPK Phosphorylation in Rat Dorsal Root Ganglion. Neuroscience, 361, 58-68. &lt;br&gt;https://doi.org/10.1016/j.neuroscience.2017.08.011</mixed-citation></ref><ref id="hanspub.44912-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Akpınar, H., Nazıroğlu, M., Övey, İ.S., Çiğ, B. and Akpınar, O. (2016) The Neuroprotective Action of Dexmedetomidine on Apoptosis, Calcium Entry and Oxidative Stress in Cerebral Ischemia-Induced Rats: Contribution of TRPM2 and TRPV1 Channels. Scientific Reports, 6, Article No. 37196. &lt;br&gt;https://doi.org/10.1038/srep37196</mixed-citation></ref><ref id="hanspub.44912-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Y., Feng, X., Hu, X., Sha, J., Li, B., Zhang, H. and Fan, H. (2018) Dexmedetomidine Ameliorates Acute Stress-Induced Kidney Injury by Attenuating Oxidative Stress and Apoptosis through Inhibition of the ROS/JNK Signaling Pathway. Oxidative Medicine and Cellular Longevity, 2018, Article ID: 4035310.  
&lt;br&gt;https://doi.org/10.1155/2018/4035310</mixed-citation></ref><ref id="hanspub.44912-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Y., Zhang, X., Zhang, B., He, G., Zhou, L. and Xie, Y. (2017) Dexmedetomidine Reduces the Neuronal Apoptosis Related to Cardiopulmonary Bypass by Inhibiting Activation of the JAK2-STAT3 Pathway. Drug Design, Development and Therapy, 11, 2787-2799. &lt;br&gt;https://doi.org/10.2147/DDDT.S140644</mixed-citation></ref><ref id="hanspub.44912-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Petrusca, D.N., Van Demark, M., Gu, Y., Justice, M.J., Rogozea, A., Hubbard, W.C. and Petrache, I. (2014) Smoking Exposure Induces Human Lung Endothelial Cell Adaptation to Apoptotic Stress. American Journal of Respiratory Cell and Molecular Biology, 50, 513-525. &lt;br&gt;https://doi.org/10.1165/rcmb.2013-0023OC</mixed-citation></ref><ref id="hanspub.44912-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Higham, A., Bostock, D., Booth, G., Dungwa, J.V. and Singh, D. (2018) The Effect of Electronic Cigarette and Tobacco Smoke Exposure on COPD Bronchial Epithelial Cell Inflammatory Responses. International Journal of Chronic Obstructive Pulmonary Disease, 13, 989-1000. &lt;br&gt;https://doi.org/10.2147/COPD.S157728</mixed-citation></ref><ref id="hanspub.44912-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wang, M., Zhang, Y., Xu, M., Zhang, H., Chen, Y., Chung, K.F., Adcock, I.M. and Li, F. (2019) Roles of TRPA1 and TRPV1 in Cigarette Smoke-Induced Airway Epithelial Cell Injury Model. Free Radical Biology and Medicine, 34, 229-238. &lt;br&gt;https://doi.org/10.1016/j.freeradbiomed.2019.01.004</mixed-citation></ref><ref id="hanspub.44912-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hong, J., Chen, Q., Wang, Y., Lin, S. and Su, G. (2020) Dexmedetomidine Alleviates Smoke-Induced Bronchial and Alveolar Epithelial Cell Injury. General Physiology and Biophysics, 39, 293-300. &lt;br&gt;https://doi.org/10.4149/gpb_2020003</mixed-citation></ref><ref id="hanspub.44912-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">陈显峰, 胡军涛, 张驰, 潘熠平, 田电声, 匡发发, 汤展宏. 右美托咪定镇静对脓毒症并发ARDS患者肺保护作用的研究[J]. 中华危重病急救医学, 2018, 30(2): 151-155.</mixed-citation></ref></ref-list></back></article>